Merck Life Science recently published a whitepaper titled “From Bench to Market: Vaccines Technology Transfer.” It covers an overview of the technology transfer process that was needed to aid global manufacturing capacities to inoculate global populations with COVID-19 vaccines. It also describes how the development and optimization of a platform to manufacture a vaccine for tropical diseases was subsequently leveraged for the SARS-CoV-2 vaccine process development and transferred to Biofarma, a leading vaccine manufacturer in Indonesia.
See here for the full paper.